Get the Stockscreener App
217.32
1.99%
-4.7021
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $217.32, with a volume of 552.30K.
It is down -1.99% in the last 24 hours and down -1.30% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$222.02
Open:
$221.84
24h Volume:
552.30K
Relative Volume:
0.50
Market Cap:
$31.72B
Revenue:
$5.40B
Net Income/Loss:
$1.49B
P/E Ratio:
21.48
EPS:
10.1168
Net Cash Flow:
$1.78B
1W Performance:
-1.64%
1M Performance:
-1.30%
6M Performance:
-15.19%
1Y Performance:
-7.07%
1-Day Range:
$215.30
$222.40
1-Week Range:
$215.30
$225.18
52-Week Range:
$215.30
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, MDLN, ALC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
217.77 | 32.34B | 5.40B | 1.49B | 1.78B | 10.12 |
ISRG
Intuitive Surgical Inc
|
464.04 | 166.81B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
149.13 | 42.73B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
44.78 | 38.25B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
75.04 | 37.05B | 10.40B | 980.00M | 1.61B | 1.9749 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | JP Morgan | Overweight |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Vanguard Group Inc. Lowers Stock Position in ResMed Inc. $RMD - MarketBeat
M&T Bank Corp Has $3.01 Million Holdings in ResMed Inc. $RMD - MarketBeat
Certuity LLC Increases Stake in ResMed Inc. $RMD - MarketBeat
Should you continue to hold Resmed stock in your portfolio? - MSN
Morgan Stanley cuts ResMed stock price target on market competition - Investing.com
Morgan Stanley cuts ResMed stock price target on market competition By Investing.com - Investing.com Canada
KeyBanc Adjusts Price Target on ResMed to $290 From $302, Maintains Overweight Rating - marketscreener.com
What Makes ASX All Ords ResMed (ASX:RMD) and Xero (ASX:XRO) Stand Out? - Kalkine Media
ResMed Inc. stock (US7611521078): Why Google Discover changes matter more now - AD HOC NEWS
ResMed, Inc. Experiences Valuation Adjustment Amid Competitive Market Landscape - Markets Mojo
ResMed Steps Up PAP Innovation With New Amalfi vs. CLA11 Sleep Apnea Study - TipRanks
Resmed Inc Annual Shareholders Meeting Transcript - GuruFocus
Earnings Preview: ResMed to Report Financial Results Post-market on April 30 - Moomoo
Is It Time To Reassess ResMed (RMD) After Recent Share Price Weakness - Yahoo Finance
Universal Beteiligungs und Servicegesellschaft mbH Buys 6,095 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc stock hits 52-week low at 218.27 USD By Investing.com - Investing.com Australia
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
ResMed (NYSE:RMD) Reaches New 52-Week LowWhat's Next? - MarketBeat
ResMed Inc stock hits 52-week low at 218.27 USD - Investing.com
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Resmed's Q3 Earnings on Deck: What's in Store for the Stock? - TradingView
ResMed Inc. $RMD Shares Purchased by KLP Kapitalforvaltning AS - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Reduces Stock Position in ResMed Inc. $RMD - MarketBeat
RMD Stock Price, Quote & Chart | RESMED INC (NYSE:RMD) - ChartMill
ResMed (RMD) Projected to Post Earnings on Thursday - MarketBeat
Global Respiratory Care Devices Market to Grow at a Substantial Growth Rate of ~8% by 2034 | DelveInsight - GlobeNewswire Inc.
OVERSEA CHINESE BANKING Corp Ltd Sells 7,795 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
Mirae Asset Global Investments Co. Ltd. Boosts Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc stock (US75102W1036): Is its sleep apnea dominance strong enough for long-term investor g - AD HOC NEWS
ResMed Inc. stock (US7611521078): Is its sleep apnea dominance strong enough for long-term investor - AD HOC NEWS
ResMed Inc. (RMD) stock price, news, quote and history - Yahoo Finance Singapore
Why ResMed (RMD) is Poised to Beat Earnings Estimates Again - Yahoo Finance
ResMed Inc. stock (US7611521078): Is the U.S. sleep apnea market strong enough to unlock new upside? - AD HOC NEWS
ResMed Inc. (RMD) Investor Outlook: Unveiling a 28% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
JPMorgan Issues Overweight Rating for ResMed Amid Sleep Apnea Shift - HarianBasis.co
JPMorgan Initiates ResMed (RMD) With “Overweight” Rating and A$37.6 PT - Insider Monkey
Mizuho Maintains ResMed Inc.Depositary Receipt (RSMDF) Outperform Recommendation - MSN
Lbp Am Sa Buys 18,142 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Should You Continue to Hold Resmed Stock in Your Portfolio? - TradingView
KBC Group NV Has $57.23 Million Position in ResMed Inc. $RMD - MarketBeat
Hendershot Investments Inc. Increases Holdings in ResMed Inc. $RMD - MarketBeat
INVESCO V.I. Health Care Fund's ResMed Inc(RMD) Holding History - GuruFocus
Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares? - The Motley Fool Australia
ResMed Inc. stock (US7611521078): Why does its sleep apnea dominance matter more now? - AD HOC NEWS
ResMed (NYSE:RMD) Now Covered by JPMorgan Chase & Co. - MarketBeat
Baird Adjusts Price Target on ResMed to $254 From $272, Maintains Neutral Rating - marketscreener.com
ResMed Inc. $RMD Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
ResMed Inc. stock (US7611521078): Is sleep apnea market growth strong enough to unlock new upside? - AD HOC NEWS
ResMed Inc. $RMD Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):